, Our study showed that RW ATTR‐AC patients closely resemble those enrolled in ATTR‐ACT. This findings have relevant implications, considering that ATTR‐AC is still considered a rare condition, and specific treatments will likely become initially available for a small proportion of the affected patients, primarily because of the relevant costs.
Real-world versus trial patients with transthyretin amyloid cardiomyopathy / Canepa M.; Tini G.; Musumeci B.; Cappelli F.; Milandri A.; Mussinelli R.; Autore C.; Perfetto F.; Rapezzi C.; Perlini S.. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - ELETTRONICO. - 21:(2019), pp. 1479-1481. [10.1002/ejhf.1563]
Real-world versus trial patients with transthyretin amyloid cardiomyopathy
Cappelli F.
Investigation
;Perfetto F.;
2019
Abstract
, Our study showed that RW ATTR‐AC patients closely resemble those enrolled in ATTR‐ACT. This findings have relevant implications, considering that ATTR‐AC is still considered a rare condition, and specific treatments will likely become initially available for a small proportion of the affected patients, primarily because of the relevant costs.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Canepa_et_al-2019-European_Journal_of_Heart_Failure.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
58.33 kB
Formato
Adobe PDF
|
58.33 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
